Boston Scientific Corp (BSX)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
- Symbol
- BSX
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Devices
- Market cap
- $62.63B
- 52 week range
- 41.94 - 105.65
Valuation
- Share price
- $42.60 (close of 2026-10-02)
- P/E (TTM)
- 17.18x
- Price to book
- 2.49x
- Price to free cash flow
- 17.28x
- Enterprise value
- $74.72B
- Book value per share
- $17.12
Price performance
| Period | Change |
|---|---|
| 1 day | -1.46% |
| 5 days | -3.01% |
| 1 month | -11.93% |
| 3 months | -5.63% |
| 6 months | -32.19% |
| Year to date | -55.32% |
| 1 year | -55.73% |
| 3 years | -19.33% |
| 5 years | -2.74% |
| 10 years | +78.99% |
| All time | +895.33% |
Members of Congress who disclosed BSX trades
Gilbert Ray Cisneros · Kevin Hern · Lisa McClain · John Boozman · Bruce Westerman · Val Hoyle · Alan Armstrong · Jefferson Shreve · Markwayne Mullin
Super investors holding BSX
Lee Ainslie (Maverick Capital LTD) · Ken Griffin (Citadel) · Sarah Ketterer (Causeway Capital Management LLC) · Ray Dalio (Bridgewater Associates) · Dodge & Cox (Dodge & Cox Funds) · Mairs & Power (Mairs & Power Inc) · Polen Capital Mgmt (Polen Capital Management LLC)
Profitability and growth
- Return on equity
- 11.82%
- Return on invested capital
- 9.19%
- Return on assets
- 6.62%
- Return on capital employed
- 9.45%
- Gross margin
- 69.01%
- Net margin
- 14.41%
- EBITDA margin
- 24.81%
- Revenue growth
- 19.87%
- Net income growth
- 56.66%
- Free cash flow growth
- 38.30%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 5.79%
- Current ratio
- 1.24x
- Net debt to EBITDA
- 2.14x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $20.07B
- Cost of revenue
- $6.22B
- Gross profit
- $13.85B
- EBITDA
- $4.98B
- Net income
- $2.89B
- Earnings per share
- $1.96
- Interest expense
- $349.00M
- Shares outstanding
- 1.48B
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $20.07B | $13.85B | $2.89B | $1.96 |
| 2024-12-31 | $16.75B | $11.49B | $1.85B | $1.26 |
| 2023-12-31 | $14.24B | $9.90B | $1.59B | $1.08 |
| 2022-12-31 | $12.68B | $8.73B | $698.00M | $0.45 |
| 2021-12-31 | $11.89B | $8.18B | $1.04B | $0.69 |
| 2020-12-31 | $9.91B | $6.45B | -$82.00M | $-0.08 |
| 2019-12-31 | $10.73B | $7.62B | $4.70B | $3.38 |
| 2018-12-31 | $9.82B | $7.01B | $1.67B | $1.21 |
| 2017-12-31 | $9.05B | $6.46B | $104.00M | $0.08 |
| 2016-12-31 | $8.39B | $5.96B | $347.00M | $0.26 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 69.01% | 14.41% | 11.82% | 9.19% |
| 2024-12-31 | 68.61% | 11.02% | 8.39% | 6.70% |
| 2023-12-31 | 69.49% | 11.18% | 8.15% | 6.93% |
| 2022-12-31 | 68.81% | 5.50% | 3.97% | 4.65% |
| 2021-12-31 | 68.78% | 8.76% | 6.26% | 7.54% |
| 2020-12-31 | 65.05% | -0.83% | -0.54% | -0.57% |
| 2019-12-31 | 70.98% | 43.78% | 33.87% | 9.84% |
| 2018-12-31 | 71.37% | 17.01% | 19.15% | 13.90% |
| 2017-12-31 | 71.34% | 1.15% | 1.48% | 5.16% |
| 2016-12-31 | 71.09% | 4.14% | 5.15% | 3.72% |
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $1.97B | - |
| 2024-12-31 | $414.00M | - |
| 2023-12-31 | $865.00M | - |
| 2022-12-31 | $928.00M | - |
| 2021-12-31 | $1.93B | - |
| 2020-12-31 | $1.73B | - |
| 2019-12-31 | $217.00M | - |
| 2018-12-31 | $146.00M | - |
| 2017-12-31 | $188.00M | $3.81B |
| 2016-12-31 | $196.00M | $5.42B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $3.66B | $299.00M |
| 2024-12-31 | $2.65B | $266.00M |
| 2023-12-31 | $1.79B | $233.00M |
| 2022-12-31 | $938.00M | $220.00M |
| 2021-12-31 | $1.32B | $194.00M |
| 2020-12-31 | $1.13B | $170.00M |
| 2019-12-31 | $1.38B | $157.00M |
| 2018-12-31 | -$6.00M | $140.00M |
| 2017-12-31 | $1.11B | $127.00M |
| 2016-12-31 | $806.00M | $116.00M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-28
- Consensus EPS estimate
- $0.76
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-07-29 | Jun/2026 | $0.83 |
| 2026-04-22 | Mar/2026 | $0.80 |
| 2026-02-04 | Dec/2025 | $0.78 |
| 2025-10-22 | Sep/2025 | $0.71 |
| 2025-07-23 | Jun/2025 | $0.72 |
| 2025-07-22 | - | - |
| 2025-04-23 | Mar/2025 | $0.67 |
| 2025-04-22 | - | - |
Filings and sources
- Company website
- bostonscientific.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Edwards Lifesciences Corp (EW) · Stryker Corp (SYK) · Dexcom Inc (DXCM) · Medtronic plc (MDT) · GE HealthCare Technologies Inc. (GEHC) · Abbott Laboratories (ABT) · STERIS plc (STE) · Universal Health Services Inc (UHS)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades